文献速递临床试验与 GCP

肝细胞癌切除术中25分钟间歇性Pringle法肝门阻断前给予地塞米松:随机对照试验方案

Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle's maneuver for hepatocellular carcinoma: protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2023-11-30

这是一项随机、双盲、双臂平行对照试验方案,纳入某区域医疗中心连续诊断为肝细胞癌并接受根治性R0/R1切除的患者,比较肝门阻断前给予地塞米松与安慰剂对术后肝功能、炎症反应及围手术期结局的影响。主要终点为术后连续7天转氨酶峰值及曲线下面积,次要终点包括总胆红素、凝血功能、炎症细胞因子、术中出血量、术后住院时间、并发症和死亡率。

要点

  • 肝细胞癌切除术前给予地塞米松,评价其减轻25分钟肝门阻断所致缺血再灌注损伤的作用。
  • 主要终点为术后连续7天转氨酶峰值及曲线下面积。
  • 次要终点包括总胆红素、凝血功能、炎症细胞因子、出血量、住院时间、并发症和死亡率。

核心结论

  • 作者认为该试验方案合理,试验结果可能具有临床意义。

研究设计与样本

  • 随机、双盲、双臂平行对照试验,纳入某区域医疗中心连续诊断为肝细胞癌并接受根治性R0/R1切除的患者,随机分配至地塞米松组或安慰剂组,外科医生、麻醉医生和结局评估者均对分组设盲。

主要发现

  • 主要终点为术后连续7天转氨酶峰值及术后转氨酶曲线下面积。
  • 次要终点为术后总胆红素、凝血功能、炎症细胞因子及其各自峰值、术中出血量、术后住院时间、并发症和死亡率。
  • 将按肝硬化和大范围肝切除进行亚组分析。

关键数值与推荐

  • 试验于2022年12月3日在中国临床试验注册中心注册,注册号ChiCTR2200066381,方案版本V1.0(20221104)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Our previous randomized controlled trial (RCT) have demonstrated that intermittent Pringle's maneuver (IPM) with a 25-min ischemic interval can be applied safely and efficiently in open or laparoscopic hepatectomy in patients with hepatocellular carcinoma (HCC) patients. But prolonging the hepatic inflow blocking time will inevitably aggravate the ischemia-reperfusion injury (IRI) caused by systemic response. This RCT aims to evaluate the effect of administration of dexamethasone versus placebo before clamping the hilar pedicle on postoperative liver function, inflammatory response, and perioperative outcomes among HCC patients undergoing liver resection with 25-min hepatic inflow occlusion. METHODS AND ANALYSIS: This will be a randomized, dual-arm, parallel-group, double-blinded trial. All eligible and consecutive patients are coming from a regional medical center who are diagnosed with HCC and underwent radical R0/R1 resection. All participates are randomly allocated in dexamethasone group or placebo group. All surgeons, anesthesiologists, and outcome assessors will be blinded to allocation status. Primary endpoints are transaminase-based postoperative hepatic injury on seven consecutive days after surgery and assessed by their peak values as well as area under the curve (AUC) of the postoperative course of aminotransferases. Secondary endpoints are postoperative total bilirubin (TBil), coagulation function, inflammatory cytokines and their respective peaks, intraoperative blood loss, postoperative hospital stay, morbidity, and mortality. The above parameters will be compared using the corresponding statistical approach. Subgroup analysis will be performed according to the liver cirrhosis and major hepatectomy. DISCUSSION: Based on our previous study, we will explore further the effect of glucocorticoid administration on attenuating the surgical stress response in order to follow securely 25-min hepatic inflow occlusion. Therefore, the trial protocol is reasonable and the results of the trial may be clinically significant. TRIAL REGISTRATION: This trial was registered on 3 December 2022, in the Chinese Clinical Trial Registry ( http://www.chictr.org.cn ), ChiCTR2200066381. The protocol version is V1.0 (20221104).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Huang Y, Xu L, Wang N, et al. Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle's maneuver for hepatocellular carcinoma: protocol for a randomized controlled trial. Trials. 2023. PMID: 38037035. doi:10.1186/s13063-023-07820-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。